Company: ARWR
Filing Date: 2025-03-07
Form Type: 424B7
Source: 0001193125-25-049889
Chunk: 4

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-03-07
Form: 424B7
Chunk 4
---
 the accompanying prospectus. You should also carefully consider the matters discussed in the section in this prospectus supplement titled “Risk Factors” and in the accompanying prospectus and in other periodic reports incorporated herein by reference.

Our Company

We develop medicines that treat
intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, our therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target
genes. Our most advanced candidate, plozasiran, has completed a Phase 3 study in patients with familial chylomicronemia syndrome (FCS) and expects to have its first commercial launch in 2025. On January 17, 2025, we announced that the United
States Food and Drug Administration accepted our New Drug Application for plozasiran. Our pipeline of 16 clinical stage investigational medicines range in development stage from Phase 1 to Phase 3. In addition, we have a robust discovery stage
pipeline which is capable of generating multiple new clinical candidates each year.

We endeavor to serve unmet medical needs and change lives leveraging
the versatility of our proprietary RNAi-based technology. We are acutely aware of the urgent need to develop solutions for the many diseases that have genetic targets that are otherwise undruggable by small molecules or biologics. To that end, we
embraced our bold goal and strive to have 20 individual drugs, either partnered or wholly owned, in clinical trials or on the market in 2025.

Corporate Information

Our executive offices are located
at 177 E. Colorado Blvd., Suite 700, Pasadena, CA 91105, and our telephone number is (626) 304-3400. Additional information regarding our company, including our audited financial statements and descriptions of
our business, is contained in the documents incorporated by reference in this prospectus. See “Where You Can Find More Information” on page S-12 and “Incorporation of Certain Information by Reference” on page S-13 of this prospectus supplement.

S-3

THE OFFERING Pursuant to this prospectus supplement, the Selling Stockholder is offering on a resale basis an aggregate of 11,926,301 Shares held by the Selling Stockholder and issued pursuant to the Purchase Agreement.

| Shares offered by the Selling Stockholder | 11,926,301 Shares. |

| Use of Proceeds | We will not receive any of the proceeds from the sale